You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,680,111

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,680,111 protect, and when does it expire?

Patent 8,680,111 protects LORBRENA and is included in one NDA.

This patent has fifty-four patent family members in forty-four countries.

Summary for Patent: 8,680,111
Title:Macrocyclic derivatives for the treatment of diseases
Abstract: The invention relates to compounds of formula (.PHI.) ##STR00001## as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Inventor(s): Bailey; Simon (San Diego, CA), Burke; Benjamin Joseph (San Diego, CA), Collins; Michael Raymond (San Diego, CA), Cui; Jingrong Jean (San Diego, CA), Deal; Judith Gail (Wildomar, CA), Hoffman; Robert Louis (San Marcos, CA), Huang; Qinhua (San Diego, CA), Johnson; Ted William (Carlsbad, CA), Kania; Robert Steven (San Diego, CA), Kath; John Charles (La Mesa, CA), Le; Phuong Thi Quy (San Diego, CA), McTigue; Michele Ann (Encinitas, CA), Palmer; Cynthia Louise (La Mesa, CA), Richardson; Paul Francis (San Diego, CA), Sach; Neal William (San Diego, CA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:13/786,106
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,680,111

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer Inc LORBRENA lorlatinib TABLET;ORAL 210868-001 Nov 2, 2018 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Pfizer Inc LORBRENA lorlatinib TABLET;ORAL 210868-002 Nov 2, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,680,111

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 090230   Start Trial
Australia 2013229173   Start Trial
Brazil 112014022106   Start Trial
Canada 2863892   Start Trial
Chile 2014002084   Start Trial
China 104169286   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.